| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Centers for Experimental Therapeutics* and Neurodegenerative Disease Research, and the Departments of Pharmacology, Pathology, and Laboratory Medicine, Institute on Aging, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
Alzheimer’s disease (AD) is a chronic neurodegenerative disorder that impairs cognition and behavior. Although the initiating molecular events are not known, increasing evidence suggests that oxidative stress could play a functional role in its pathogenesis. Lipoxygenase (LOX) enzymes by oxidizing polyunsaturated fatty acids synthesize hydroperoxyacids, which are potent pro-oxidant mediators. Because circumstantial evidence suggests that 12/15-LOX is a major source of oxidative stress, we investigated the protein levels and activity of this enzyme in different brain regions of histopathologically confirmed AD and control cases. Using quantitative Western blot analysis we demonstrated that in affected frontal and temporal regions of AD brains the amount of 12/15-LOX was higher compared with controls, whereas no difference between the two groups was detected in the cerebellum. This observation was confirmed by immunohistochemical studies. Levels of 12/15-hydroxyeicosatetraenoic acids, metabolic products of 12/15-LOX, were also markedly elevated in AD brains compared to controls. This increase directly correlated with brain lipid peroxidation, and inversely with vitamin E levels. Finally, genetic deletion of this enzyme in vitro resulted in a reduction of the cellular oxidative stress response after incubation with H2O2 or amyloid ß. These data show that the 12/15-LOX metabolic pathway is increased and correlates with an oxidative imbalance in the AD brain, implying that this enzyme might contribute to the pathogenesis of this neurodegenerative disorder.
This article has been cited by other articles:
 |
|
 |
|
  M. D. Ikonomovic, E. E. Abrahamson, T. Uz, H. Manev, and S. T. DeKosky Increased 5-Lipoxygenase Immunoreactivity in the Hippocampus of Patients With Alzheimer's Disease J. Histochem. Cytochem., December 1, 2008; 56(12): 1065 - 1073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. A. Butovich and S. M. Lukyanova Inhibition of lipoxygenases and cyclooxygenases by linoleyl hydroxamic acid: comparative in vitro studies J. Lipid Res., June 1, 2008; 49(6): 1284 - 1294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Firuzi, J. Zhuo, C. M. Chinnici, T. Wisniewski, and D. Pratico 5-Lipoxygenase gene disruption reduces amyloid-{beta} pathology in a mouse model of Alzheimer's disease FASEB J, April 1, 2008; 22(4): 1169 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Chinnici, Y. Yao, T. Ding, C. D. Funk, and D. Pratico Absence of 12/15 Lipoxygenase Reduces Brain Oxidative Stress in Apolipoprotein E-Deficient Mice Am. J. Pathol., November 1, 2005; 167(5): 1371 - 1377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. J. F. Tietge, D. Pratico, T. Ding, C. D. Funk, R. B. Hildebrand, T. Van Berkel, and M. Van Eck Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress J. Lipid Res., August 1, 2005; 46(8): 1604 - 1614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Montine and J. D. Morrow Fatty Acid Oxidation in the Pathogenesis of Alzheimer's Disease Am. J. Pathol., May 1, 2005; 166(5): 1283 - 1289. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
